Literature DB >> 9686810

Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients.

J H Dangel1.   

Abstract

Cardiovascular abnormalities were evaluated in 64 children aged between 1 year 9 months and 25 years with mucopolysaccharidoses (MPS) and related disorders. A heart murmur was heard in 18 patients, but in only 6 was it characteristic for specific valvular lesions. Echocardiography was performed in 63 children. In one girl cardiac lesions were diagnosed on autopsy. In 46 patients (72%), valvular lesions and/or different types of cardiomyopathy were detected. There were no characteristic changes for different types of MPS. In the majority of children in whom dermatan sulphate accumulated, cardiac involvement was the most frequent (88%) and severe. The most common lesion, regardless of MPS type, was thickening of the mitral valve (66%), with regurgitation or stenosis in 28 (44%). Aortic valve thickening was detected in 17 patients (27%), asymmetric septal hypertrophy or hypertrophic cardiomyopathy in 18, congestive cardiomyopathy in 1 and endocardial thickening in 13 patients. Cardiac involvement was less frequent in children with Sanfilippo disease. Two or more echocardiographic examinations were performed in 23 patients. In 19 of them (83%) cardiac changes were more severe during the second examination. One 7-year-old boy with Hunter disease underwent successful mitral valve replacement. CONCLUSIONS; Cardiac involvement is present in most patients with MPS although there are few clinical signs and symptoms. The most common and severe changes are in Hurler, Hunter, Maroteaux-Lamy and I-cell disease, rarely in Sanfilippo disease. Mitral valve deformation is most frequent in all patients. The cardiac lesions are progressive.

Entities:  

Mesh:

Year:  1998        PMID: 9686810     DOI: 10.1007/s004310050872

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  46 in total

1.  Hand and foot abnormalities associated with genetic diseases.

Authors:  Henry J Mankin; Jesse Jupiter; Carol Ann Trahan
Journal:  Hand (N Y)       Date:  2010-10-26

2.  Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.

Authors:  Nathan J Palpant; Fikru B Bedada; Brandon Peacock; Bruce R Blazar; Joseph M Metzger; Jakub Tolar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

3.  Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.

Authors:  A Hinek; S E Wilson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Natural history of echocardiographic abnormalities in mucopolysaccharidosis III.

Authors:  Carolyn M Wilhelm; Kristen V Truxal; Kim L McBride; John P Kovalchin; Kevin M Flanigan
Journal:  Mol Genet Metab       Date:  2018-04-27       Impact factor: 4.797

5.  Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.

Authors:  Roberto Giugliani; Christina Lampe; Nathalie Guffon; David Ketteridge; Elisa Leão-Teles; James E Wraith; Simon A Jones; Cheri Piscia-Nichols; Ping Lin; Adrian Quartel; Paul Harmatz
Journal:  Am J Med Genet A       Date:  2014-04-24       Impact factor: 2.802

6.  Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I.

Authors:  L Schroeder; P Orchard; C B Whitley; J M Berry; J Tolar; W Miller; E A Braunlin
Journal:  JIMD Rep       Date:  2013-02-12

7.  Left ventricular outflow tract obstruction as a consequence of Sanfilippo's disease.

Authors:  J de Geest; L Cozijnsen; C E Essed; B P M van Nesselrooij
Journal:  Neth Heart J       Date:  2002-10       Impact factor: 2.380

8.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06

9.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.